Recent news on Olmesartan Medoxomil

Olmesartan Medoxomil and Hydrochlorothiazide Work Better Together ...  -  May 24, 2007
DG NewsCHICAGO, IL -- May 23, 2007 -- Combining the angiotensin II receptor blocker olmesartan medoxomil and hydrochlorothiazide (HCTZ) increases blood pressure

Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure ...  -  May 21, 2007
Earthtimes.orgBenicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil-hydrochlorothiazide), an angiotensin

Amlodipine And Olmesartan Study Results Released; Late Breaker ...  -  May 22, 2007
Medical News Today (press release),Combining the calcium channel blocker amlodipine besylate with the angiotensin receptor blocker olmesartan medoxomil, produced significant mean reductions

Amlodipine and Olmesartan Study Results Released; Late Breaker ...  -  May 21, 2007
PR Newswire (press release),This investigational agent of amlodipine besylate/olmesartan medoxomil (AZOR(TM)) is under regulatory review in the United States, including trade name

Amlodipine and Olmesartan Study Results Released; Late Breaker ...  -  May 21, 2007
Earthtimes.orgPARSIPPANY, NJ, May 21 -- Combining the calcium channel blocker amlodipine besylate with the angiotensin receptor blocker olmesartan medoxomil,

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce ...  -  May 23, 2007
PharmaLive.com (press release),Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin

Forest Laboratories, Inc. Reports Fiscal Year 2007 Fourth Quarter ...  -  Apr 24, 2007
PR-Inside.com (Pressemitteilung),...earnings contribution of $45870000 from the co-promotion of Benicar(R) (olmesartan medoxomil) and Benicar HCT(R), antihypertensive therapies,

Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal ...  -  Apr 12, 2007
Drug Newswire (press release),Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin

Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to ...  -  Mar 29, 2007
Drug Newswire (press release),Daiichi Sankyo's portfolio includes BENICAR(R) (olmesartan medoxomil) and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Daiichi Sankyo, Inc. Announces Filing for WelChol Label Change to ...  -  Mar 28, 2007
WM Experts (press release),Daiichi Sankyo's portfolio includes BENICAR® (olmesartan medoxomil) and BENICAR HCT® (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Daiichi Sankyo Announces Completion of Phase I Trial on the Anti ...  -  Apr 19, 2007
PharmaLive.com (press release),...on the Japanese market, including the antihypertensive Benicar (olmesartan medoxomil) and the synthetic antibacterial agent Cravit (levofloxacin).

Forest Laboratories Announces Rule 144 Sale by Executive Officer  -  Feb 15, 2007
Drug Newswire (press release),Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil-hydrochlorothiazide), an angiotensin

DAIICHI SANKYO returns development rights of KAI-9803  -  Feb 9, 2007
PipelineReview.com (press release),...on the Japanese market, including the antihypertensive Benicar® (olmesartan medoxomil) and the synthetic antibacterial agent Cravit® (levofloxacin).

Forest Laboratories, Inc. Reports Q3'07 Diluted Earnings Per Share ...  -  Jan 16, 2007
Drug Newswire (press release),...earnings contribution of $38664000 from the co-promotion of Benicar(R)* (olmesartan medoxomil) and Benicar HCT(R), antihypertensive therapies,

Forest Laboratories Announces Completion of Acquisition of Cerexa ...  -  Jan 11, 2007
Yahoo! News (press release)Alzheimer's disease; Benicar®* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT® (olmesartan medoxomil- hydrochlorothiazide),

Forest Labs Q3 Profit Surges 28% Helped By Namenda, Lexapro Sales ...  -  Jan 16, 2007
Trading Markets,Sales benefited from the contribution of $38.6 million from the co-promotion of Benicar (olmesartan medoxomil) and Benicar HCT antihypertensive therapies,

Daiichi Sankyo, Inc. Announces Filing Of Supplemental New Drug ...  -  Jan 3, 2007
Medical News Today (press release),Daiichi Sankyo's portfolio includes BENICAR(R) (olmesartan medoxomil) and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Daiichi Sankyo, Inc. Announces Filing Of Supplemental New Drug ...  -  Jan 3, 2007
PipelineReview.com (press release),Daiichi Sankyo's portfolio includes BENICAR® (olmesartan medoxomil) and BENICAR HCT® (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Daiichi Sankyo Files New Drug Application for Amoldipine Beslyte ...  -  Nov 30, 2006
Japan Corporate News (press release),...blocker (CCB) amlodipine besylate (currently marketed by Pfizer as Norvasc) and the angiotensin receptor blocker (ARB) olmesartan medoxomil, or Benicar.

Daiichi Sankyo, Inc. Announces Filing of New Drug Application for ...  -  Nov 29, 2006
PipelineReview.com (press release),Daiichi Sankyo's portfolio includes BENICAR(R) (olmesartan medoxomil) and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Daiichi Sankyo, Inc. Announces Filing of New Drug Application for ...  -  Nov 28, 2006
Market Wire (press release)Daiichi Sankyo's portfolio includes BENICAR® (olmesartan medoxomil) and BENICAR HCT® (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus ...  -  Dec 14, 2006
Drug Newswire (press release),Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin

Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus ...  -  Dec 14, 2006
Yahoo! News (press release)Alzheimer's disease; Benicar®* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT® (olmesartan medoxomil- hydrochlorothiazide),

US Food and Drug Administration Issues Non-Approvable Letter for ...  Oct 24, 2006
...aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin ... -Drug Newswire (press release), Patient Recruitment For Desmoteplase Phase IIB/III Stroke Study ...  Oct 26, 2006
D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R) (olmesartan medoxomil), an angiotensin ... -Medical News Today (press release), Forest Laboratories Reports Earnings Per Share of $0.75 for Q2'07  Oct 17, 2006
...in net revenues was other income of $68,299,000 which includes $48,315,000 in earnings contribution from the Benicar(R)* (olmesartan medoxomil) co-promotion ... -MSN Money Forest Laboratories Inc. Announces Appointment of Dr. Lawrence S. ...  Sep 7, 2006
...aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate and severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin ... -PR Newswire

Daiichi Sankyo to Invest in Kearney Venture Partners, LP  Sep 8, 2006
Pharmaceutical have a broad range of major drug products on the Japanese market, including the antihypertensive Olmetec(R) (olmesartan medoxomil), which is ... -PR Newswire

Daiichi Sankyo Files New Drug Application for Amoldipine Beslyte ...  -  12 Dec 2006
Japan Corporate News (press release),...blocker (CCB) amlodipine besylate (currently marketed by Pfizer as Norvasc) and the angiotensin receptor blocker (ARB) olmesartan medoxomil, or Benicar.

Daiichi Sankyo, Inc. Announces Filing of New Drug Application for ...  -  12 Dec 2006
PipelineReview.com (press release),Daiichi Sankyo's portfolio includes BENICAR(R) (olmesartan medoxomil) and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Daiichi Sankyo, Inc. Announces Filing of New Drug Application for ...  -  12 Dec 2006
Market Wire (press release)Daiichi Sankyo's portfolio includes BENICAR® (olmesartan medoxomil) and BENICAR HCT® (olmesartan medoxomil/hydrochlorothiazide), the fastest growing

Lexapro(R) Demonstrated Significance On Prospectively Defined ...  -  Dec 7, 2006
Medical News Today (press release),Benicar(R) (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotenisn

Sales of Antihypertensive Agent Olmetec Begin in China  Aug 2, 2006
2006 from the Chinese SFDA (State Food Drug Administration) to manufacture the antihypertensive agent Olmetec® (generic name: olmesartan medoxomil) and began ... -PharmaLive.com

Sankyo Commences Patent Litigation Against Benicar  Aug 2, 2006
States District Court for the District of New Jersey for infringement of Sankyo’s US patent (hereinafter Patent) covering olmesartan medoxomil, the active ... -ag-IP-news Agency

Sankyo to Manufacture, distribute Olmetic Antihypertensive Drug in ...  Aug 4, 2006
...of the Daiichi Sankyo Company, will start selling Olmetec - generic name: olmesartan medoxomil - an antihypertensive agent in July. ... -Japan Corporate News

YM Biosciences Licenses Monoclonal Antibody, Nimotuzumab, to ...  Jul 31, 2006
Irrinotecan Hcl, in Japan and have a broad range of major drug products in that market, including the antihypertensive Olmetec® (olmesartan medoxomil) and the ... -Yahoo! News

YM Biosciences Licenses Monoclonal Antibody, Nimotuzumab, to ...  Jul 31, 2006
Hcl, in Japan and have a broad range of major drug products in that market, including the antihypertensive Olmetec(R) (olmesartan medoxomil) and the synthetic ... -PharmaLive.com

Daiichi Wins Floxin Otic Patent Challenge by Generic Manufacturer ...  Aug 3, 2006
Pharmaceutical have a broad range of major drug products on the Japanese market, including the antihypertensive Olmetec® (olmesartan medoxomil) and the ... -PharmaLive.com

Forest Laboratories, Inc. Reports Fiscal First Quarter 2007 ...  Jul 18, 2006
...in net revenues was other income of $57,570,000 which includes $41,717,000 in earnings contribution from the Benicar(R)* (olmesartan medoxomil) co-promotion ... -MSN Money

Forest Announces Federal Court Upholds Lexapro(R) Patent  Jul 13, 2006
...aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin ... -International News Service

1st Clinical Trial To Show Colesevelam HCl Plus Stable Oral ...  Jun 26, 2006
Daiichi Sankyo's portfolio includes BENICAR® (olmesartan medoxomil), the fastest growing angiotensin receptor blocker on the market (1). For more information ... -Medical News Today



Forest Laboratories, Inc. Reports Q4'06 Diluted Earnings Per Share ...  Apr 25, 2006
...aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar®* (olmesartan medoxomil), an angiotensin ... - Yahoo! News

Forest Laboratories Signs Grants Manager Agreement With Fast Track ...  Apr 19, 2006
...aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar® * (olmesartan medoxomil), an angiotensin ... - Market Wire

Forest Laboratories Fiscal 2007 Guidance  Apr 26, 2006
...aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin ... - Webbolt Business News



Forest and Almirall Announce a Development and Marketing ...  Apr 10, 2006
...aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin ... - PR Newswire

US Subsidiaries Join Together to Form Daiichi Sankyo, Inc.  Apr 3, 2006
As of today's announcement, the sales force now supports six products, including BENICAR(R) (olmesartan medoxomil), BENICAR(R) HCT (olmesartan medoxomil ... - PR Newswire

MorphoSys and Japanese Pharmaceutical Group Daiichi Sankyo Form ...  Mar 16, 2006
Pharmaceutical have a broad range of major drug products on the Japanese market, including the antihypertensive Benicar® (olmesartan medoxomil) and the ... - WebWire

Study Shows More Potent and More Reliable Platelet Inhibition with ...  Mar 14, 2006
Pharmaceutical have a broad range of major drug products on the Japanese market, including the antihypertensive Benicar(R) (olmesartan medoxomil) and the ... - Finanzen.net



Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share ...  Jan 17, 2006
...aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R) * (olmesartan medoxomil), an angiotensin ... - MSN Money

KAI Pharmaceuticals, Inc. and Sankyo Company, Limited Enter Global ...  Jan 9, 2006
...of significant contributions to the treatment of cardiovascular disease, with products such as Benicar® and Olmetec® (olmesartan medoxomil) and Pravachol ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional